Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Paclitaxel

FDA-approved product (injectable, injection), marketed as Abraxane, Paclitaxel, Taxol.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Paclitaxel
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • Carcinoma
  • HER2 Positive Breast Carcinoma
  • Kaposi's sarcoma
  • Malignant Pancreatic Neoplasm
  • Neoplasm
  • Non-small cell lung carcinoma
  • Ovarian cancer
  • Ovarian carcinoma
  • Ovarian neoplasm
  • Pancreatic carcinoma
  • Pancreatic neoplasm
  • Undifferentiated carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Taxanes
FDA pharmacologic class
Microtubule Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis42.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Paclitaxel in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Paclitaxel with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma

    NCT02037048 · start 2014-02-10

    Registered record
    Registry ID
    NCT02037048
    Conditions
    Adenocarcinoma of the Esophagus; Adenocarcinoma of the Gastroesophageal Junction; Adenocarcinoma of the Gastric Cardia; Stage IIIA Esophageal Cancer; Stage IIIB Esophageal Cancer; Stage IIIC Esophageal Cancer
    Interventions
    oxaliplatin; leucovorin calcium; fluorouracil; therapeutic conventional surgery; radiation therapy; carboplatin; paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2014-02-10
    Completion
    2025-10-01
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenocarcinoma of the Esophagus; Adenocarcinoma of the Gastroesophageal Junction; Adenocarcinoma of the Gastric Cardia; Stage IIIA Esophageal Cancer +2 more
    Interventionoxaliplatin; leucovorin calcium; fluorouracil; therapeutic conventional surgery +3 more
    PhasePhase 2
    Registry statusUnknown

  • A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer

    NCT01711970 · start 2012-11

    Registered record
    Registry ID
    NCT01711970
    Conditions
    Platinum Resistant Ovarian Cancer
    Interventions
    Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2012-11
    Completion
    2017-05-03
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlatinum Resistant Ovarian Cancer
    InterventionPaclitaxel
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

    NCT01612351 · start 2012-06

    Registered record
    Registry ID
    NCT01612351
    Conditions
    Head and Neck Cancer; Squamous Cell Carcinoma of the Head and Neck
    Interventions
    Carboplatin; Paclitaxel; Lapatinib; Cisplatin; Cisplatin; Ipsilateral Radiation; Bilateral Radiation; Transoral Surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-06
    Completion
    2025-05-19
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead and Neck Cancer; Squamous Cell Carcinoma of the Head and Neck
    InterventionCarboplatin; Paclitaxel; Lapatinib; Cisplatin +4 more
    PhasePhase 2
    Registry statusCompleted

  • Assessment Of Stromal Response To Nab-Paclitaxel In Combination With Gemcitabine In Pancreatic Cancer

    NCT01442974 · start 2011-01

    Registered record
    Registry ID
    NCT01442974
    Conditions
    Pancreatic Cancer
    Interventions
    Gemcitabine plus nab-paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-01
    Completion
    2012-06
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Cancer
    InterventionGemcitabine plus nab-paclitaxel
    PhaseNot applicable
    Registry statusCompleted

  • Metronomic Therapy in Metastatic Breast Cancer.

    NCT01131195 · start 2010-07-19

    Registered record
    Registry ID
    NCT01131195
    Conditions
    Breast Cancer
    Interventions
    bevacizumab, Paclitaxel; Bevacizumab, Cyclophosphamide, Capecitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-07-19
    Completion
    2018-02-28
    Enrolment
    139

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    Interventionbevacizumab, Paclitaxel; Bevacizumab, Cyclophosphamide, Capecitabine
    PhasePhase 3
    Registry statusCompleted

  • A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols

    NCT01369433 · start 2010-06

    Registered record
    Registry ID
    NCT01369433
    Conditions
    Solid Tumors
    Interventions
    Tivozanib + paclitaxel; Tivozanib + temsirolimus; Tivozanib; Tivozanib (AV-951); Tivozanib + capecitabine; Tivo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2010-06
    Completion
    2015-10
    Enrolment
    225

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumors
    InterventionTivozanib + paclitaxel; Tivozanib + temsirolimus; Tivozanib; Tivozanib (AV-951) +2 more
    PhaseNot applicable
    Registry statusTerminated

  • First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

    NCT01097746 · start 2010-04-14

    Registered record
    Registry ID
    NCT01097746
    Conditions
    Fallopian Tube Carcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; FIGO Stage III Ovarian Cancer; FIGO Stage IIIA Ovarian Cancer; FIGO Stage IIIA1 Ovarian Cancer; FIGO Stage IIIA1(i) Ovarian Cancer; FIGO Stage IIIA1(ii) Ovarian Cancer; FIGO Stage IIIA2 Ovarian Cancer; FIGO Stage IIIB Ovarian Cancer; FIGO Stage IIIC Ovarian Cancer; FIGO Stage IVA Ovarian Cancer; FIGO Stage IVB Ovarian Cancer; Malignant Ovarian Brenner Tumor; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Ovarian Undifferentiated Carcinoma; Primary Peritoneal Carcinoma; Primary Peritoneal Serous Adenocarcinoma
    Interventions
    Bevacizumab; Carboplatin; Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-04-14
    Completion
    2022-09-13
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFallopian Tube Carcinoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma +23 more
    InterventionBevacizumab; Carboplatin; Paclitaxel
    PhasePhase 2
    Registry statusCompleted

  • Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer

    NCT01108055 · start 2010-04

    Registered record
    Registry ID
    NCT01108055
    Conditions
    Bladder Cancer; Bladder (Urothelial, Transitional Cell) Cancer; Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive); Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy); Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable
    Interventions
    Pazopanib (GW786034); Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-04
    Completion
    2015-07
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBladder Cancer; Bladder (Urothelial, Transitional Cell) Cancer; Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive); Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy) +1 more
    InterventionPazopanib (GW786034); Paclitaxel
    PhasePhase 2
    Registry statusCompleted

  • Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC)

    NCT00686322 · start 2008-04

    Registered record
    Registry ID
    NCT00686322
    Conditions
    Non-small-cell Lung Cancer
    Interventions
    Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-04
    Completion
    2009-10
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small-cell Lung Cancer
    InterventionConcurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)
    PhasePhase 4
    Registry statusCompleted

  • A Phase 1b/2 Study of AMG 655 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer

    NCT00534027 · start 2008-01

    Registered record
    Registry ID
    NCT00534027
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    AMG 655; AMG 655 placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2008-01
    Completion
    2011-03
    Enrolment
    172

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionAMG 655; AMG 655 placebo
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors

    NCT00607048 · start 2007-11

    Registered record
    Registry ID
    NCT00607048
    Conditions
    Neoplasms
    Interventions
    Paclitaxel + Carboplatin + CP-870,893; Paclitaxel + Carboplatin + CP-870,893
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-11
    Completion
    2009-07
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms
    InterventionPaclitaxel + Carboplatin + CP-870,893; Paclitaxel + Carboplatin + CP-870,893
    PhasePhase 1
    Registry statusCompleted

  • Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer

    NCT00352300 · start 2006-06

    Registered record
    Registry ID
    NCT00352300
    Conditions
    Fallopian Tube Carcinoma; Infectious Disorder; Neutropenia; Ovarian Carcinosarcoma; Primary Peritoneal Carcinoma; Stage III Ovarian Cancer; Stage IV Ovarian Cancer
    Interventions
    Adjuvant Therapy; Carboplatin; Paclitaxel; Pegfilgrastim
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-06
    Completion
    Not recorded
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFallopian Tube Carcinoma; Infectious Disorder; Neutropenia; Ovarian Carcinosarcoma +3 more
    InterventionAdjuvant Therapy; Carboplatin; Paclitaxel; Pegfilgrastim
    PhasePhase 1
    Registry statusCompleted

  • EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas

    NCT00377936 · start 2005-09

    Registered record
    Registry ID
    NCT00377936
    Conditions
    Adenocarcinoma; Metastasis; Pancreas Neoplasms
    Interventions
    Gemcitabine alone; EndoTAG-1 and Gemcitabine; EndoTAG-1 and Gemcitabine; EndoTAG-1 and Gemcitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-09
    Completion
    2008-10
    Enrolment
    212

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenocarcinoma; Metastasis; Pancreas Neoplasms
    InterventionGemcitabine alone; EndoTAG-1 and Gemcitabine; EndoTAG-1 and Gemcitabine; EndoTAG-1 and Gemcitabine
    PhasePhase 2
    Registry statusCompleted

  • Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer

    NCT00110695 · start 2005-04

    Registered record
    Registry ID
    NCT00110695
    Conditions
    Breast Neoplasms
    Interventions
    Nanoparticle albumin bound paclitaxel followed by FEC
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-04
    Completion
    2008-07
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Neoplasms
    InterventionNanoparticle albumin bound paclitaxel followed by FEC
    PhasePhase 2
    Registry statusCompleted

  • Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2

    NCT00085839 · start 2004-02

    Registered record
    Registry ID
    NCT00085839
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    Tarceva (Trademark) (erlotinib HCl, OSI-774); Combination carboplatin and paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-02
    Completion
    2007-03
    Enrolment
    103

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionTarceva (Trademark) (erlotinib HCl, OSI-774); Combination carboplatin and paclitaxel
    PhasePhase 2
    Registry statusCompleted